Claes Ohlsson
Claes Ohlsson says: “With increasing age of the population, we are facing a substantial increase in bone fragility fractures, which account for considerable disease burden and costs. Therefore we aim to improve the prevention, diagnosis and treatment of osteoporosis and related fractures. We will identify human genetic signals for a variety of specific fracture-related phenotypes and translate these to novel mechanisms regulating fracture risk. The clinical usefulness of the most promising genetic markers will be evaluated in the fracture risk prediction tool FRAX® that, according to national guidelines in Sweden and many other countries, should be used to aid in fracture risk prediction and thereby in the selection of individuals who would benefit most from osteoporosis treatment. Our vision is to develop fracture type-specific diagnostic tools and treatments facilitating a more personalized anti-fracture therapy.”